Securing Contract Testing Capacity During the COVID-19 Pandemic
First written in FY2020. 4 of 11 entries say "Advanced", first in FY2021. Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025ReframedAnnual report
「To meet continued strong demand for PXB mice, the company is pursuing phased production increases through outsourced breeding and plans to consider a production expansion strategy with high investment efficiency. In addition, to continue providing high-quality PXB mice, the company is establishing a system under which its quality control department centrally manages and appropriately feeds back information on mice after delivery received from domestic and overseas customers and partner CROs.」
The company is reshaping its measures from securing supply capacity primarily through expansion of KMT’s in-house production facilities to phased production increases through outsourced breeding and a system for centralized management of quality information. - FY2023AdvancedAnnual report
「The Group is developing its supply structure and working to secure contract-testing capacity, including through partner CROs.」
To meet increased customer demand, the company continues to develop its supply structure and secure contract-testing capacity, including through partner CROs. It also reports that the order backlog is being worked through as production returns to normal. - FY2023-Q3AdvancedAnnual report
「Although order intake was slightly below the level of the previous year, when several large projects were won, it exceeded plan, and the order backlog is being worked down smoothly as the production-process problems that occurred in the previous fiscal year have been resolved.」
The company states that defects in the production process during the previous fiscal year have been resolved, putting it in a position to steadily work through its order backlog. Specific improvements resulting from efforts to secure contract-testing capacity are indicated. - FY2023-Q2RestatedAnnual report
「As part of this structure, we are making capital investments at KMT Hepatech,Inc., our overseas production base, to increase PXB mouse supply capacity. Going forward, we aim to stabilize PXB mouse production at the company while working to reduce costs through greater efficiency.」
The company continues measures at overseas production sites to increase capital investment, expand supply capacity, stabilize and improve production, and reduce costs through greater efficiency. - FY2023-Q1RestatedAnnual report
「As part of this structure, we are making capital investments at KMT Hepatech,Inc., our overseas production base, to increase PXB mouse supply capacity. Going forward, we aim to stabilize PXB mouse production at the company while working to reduce costs through greater efficiency.」
The company continues measures at overseas production sites to increase capital investment, expand supply capacity, stabilize and improve production, and reduce costs through greater efficiency. - FY2022WorsenedAnnual report
「However, a temporary decline in PXB mouse production due to defects in production processes at domestic production facilities and supply shortages caused by delays at overseas production facilities became factors reducing revenue.」
While advancing efforts to increase production and secure capacity, supply shortages caused by domestic process defects and overseas production delays materialized as a factor reducing revenue. - FY2022-Q3Prioritizing customer supply and increasing productionAnnual report
「The Group is prioritizing the provision of mice to customers while working to increase production volumes.」
In response to supply shortages and their impact on order activities, the company explicitly states that it is prioritizing the provision of mice to customers and working to increase production volumes. - FY2022-Q2Supply constraints caused by delays and defects in overseas and domestic productionAnnual report
「However, delays in production at overseas production facilities where capital investment had been completed, together with defects in production processes at domestic production facilities, caused PXB mouse production to remain below the initial plan and made the supply shortage pronounced.」
The company reports that production delays at overseas production facilities and process defects at domestic production facilities made the supply shortage pronounced despite efforts to increase production and secure supply capacity. - FY2022-Q1AdvancedAnnual report
「Meanwhile, as shortages of mice have persisted due to increasing demand for PXB mice, our group has worked to stabilize production by increasing output, including at overseas production sites.」
To address increased demand and mouse shortages, the company is securing contract-testing and supply capacity through an increased-production structure that includes overseas production sites. - FY2021AdvancedAnnual report
「The Group is increasing PXB mouse production and working to secure contract-testing capacity, including through partner CROs.」
To address demand for outsourcing resulting from restrictions on the use of customers’ facilities, the company is increasing PXB mouse production and securing contract-testing capacity, including through partner CROs. - FY2020First statedAnnual report
「As pharmaceutical companies and research institutions that cannot use their own facilities are outsourcing tests that they previously conducted in-house, the Group is working to secure contract-testing capacity, including through partner CROs, in preparation for new order opportunities.」
The company views demand for outsourcing resulting from restrictions on the use of customers’ facilities as a new order opportunity and outlines measures to secure contract-testing capacity, including through partner CROs.